Navigation Links
NUCRYST Announces the Completion of the Sale of its Acticoat Business
Date:12/22/2009

PRINCETON, NJ, Dec. 22 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp. ("Nucryst") (TSX:NCS / NASDAQ:NCST) is pleased to announce the closing of the previously announced sale of substantially all of the assets of Nucryst pursuant to an asset purchase agreement dated November 10, 2009, as amended, among Nucryst, NUCRYST Pharmaceuticals Inc., Smith & Nephew Inc. and Smith & Nephew (Overseas) Limited (the "Asset Sale"). The closing of the Asset Sale was completed following approval of the transaction by Nucryst shareholders at a Special Meeting of Shareholders which was held on Monday, December 21, 2009. Of the votes cast at the meeting, 99 per cent were in favour of the Asset Sale.

The meeting was also being held to consider a special resolution (the "Amalgamation Resolution") to approve the proposed amalgamation of Nucryst with a newly formed subsidiary of The Westaim Corporation ("Westaim") to form Amalco (the "Amalgamation"). Under the Amalgamation, Nucryst shareholders other than Westaim will receive for each issued and outstanding share in Nucryst one redeemable preferred share in the capital of Amalco, which preferred share will be redeemed for US$1.77 in cash upon the completion of the Amalgamation. Although the Amalgamation Resolution was approved by Nucryst shareholders, with 99 per cent of all votes cast and 99 per cent of the votes cast by minority shareholders being in favour of the transaction, the meeting was adjourned until 10:00 am mountain time on December 31, 2009 at the same location as the December 21, 2009 meeting, following approval of the Amalgamation Resolution. The purpose of the adjournment is to afford Nucryst additional time to allow for the United States regulatory review process associated with the Amalgamation, which is a "going private" transaction under applicable United States securiti
'/>"/>

SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. NUCRYST Announces Special Meeting of Shareholders
2. NUCRYST Receives Deficiency Notice from NASDAQ
3. European Launch of Acticoat(TM) Flex with NUCRYSTs Nanocrystalline Silver Technology Announced by Smith Nephew
4. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 Second Quarter Results
5. NUCRYST announces 2009 first quarter financial results
6. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results
7. NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results
8. NUCRYST Approves $0.80 Per Share Cash Distribution to Shareholders
9. NUCRYST appoints interim CEO
10. NUCRYST Pharmaceuticals appoints a new director
11. NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Recently, the famous review website, Top10BestSEOHosting.com, has ... . According to the site, GoDaddy, Bluehost and ... the world. “Nowadays, Joomla hosting is a very ... hosting. The account owner is allowed to use ... under a specific name, brand or company,” the ...
(Date:10/25/2014)... York (PRWEB) October 25, 2014 The ... ) will be addressed in December, when the U.S. ... hearing session. According to a Hearing Session Order issued ... the matter will be heard on December 4, 2014, ... at 9:30 a.m. (In Re: Xarelto Products Liability Litigation, ...
(Date:10/25/2014)... TASC (Total Administrative Services Corporation), ... account management services, announces the release of four ... taxes, reduce administrative workload, and lessen liability. ... the efficient handling of complex, time-sensitive, and labor-consuming ... meets their goals and objectives. The four Suites ...
(Date:10/25/2014)... October 25, 2014 The federal ... http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston Scientific Corp. ... District Court, Southern District of West Virginia has ... Punitive Damages in a group of cases filed ... issued on October 21st, U.S. District Judge Joseph ...
(Date:10/25/2014)... -- Not getting the right amount of sleep might ... suggests. Those who sleep less or more than ... be more prone to developing the chronic condition, which ... authors concluded that duration and quality of sleep are ... bowel diseases. "Both short and long durations of ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: GoDaddy, Bluehost And Hostgator Are Among The Most Excellent Suppliers In The World 2Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 3Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2
... Inviting, Child-Friendly Online Information Source for ... ... http://www.searchhope.org , LOS ANGELES, March ... created an innovative, inviting,child-friendly web-based portal that allows sick children and ...
... damage that can occur in babies with congenital heart disease is ... defect results in too much blood in the lungs, more blood ... blood vessel growth is abruptly halted. , You get this burst ... we think the system gets shut down and the lungs dont ...
... NC Researchers at Duke University Medical Center say ... more harm to cardiovascular health in women than in ... Brain, Behavior and Immunity, found that poor sleep is ... biomarkers associated with elevated risk of heart disease and ...
... The Children,s,Hospital of Philadelphia is pleased to name ... Nursing Officer. The appointment follows an,extensive national search., ... coming to Children,s Hospital, Esposito-Herr served as the ... of Maryland Medical,Center, where she also held a ...
... Inc. (Nasdaq: GTIV ), the nation,s leading provider ... scheduled to,present from 8:30 a.m. to 8:55 a.m. ET, ... Global Healthcare Conference in Miami,Florida., The event will ... web cast,which may be accessed by visiting http://investors.gentiva.com/events.cfm ...
... stunted growth , , MONDAY, March 10 (HealthDay News) -- ... patients at risk for bone damage and stunted growth, ... concerns a signal transduction inhibitor (STI) medication known as ... by short-circuiting tumor growth on the molecular level. The ...
Cached Medicine News:Health News:Siegel+Gale Designs New 'HOPE Portal' for Childrens Hospital Los Angeles 2Health News:Siegel+Gale Designs New 'HOPE Portal' for Childrens Hospital Los Angeles 3Health News:Lung damage in babies with congenital heart disease under study 2Health News:Lung damage in babies with congenital heart disease under study 3Health News:Poor sleep more dangerous for women 2Health News:Poor sleep more dangerous for women 3Health News:The Children's Hospital of Philadelphia Appoints New Chief Nursing Officer 2Health News:Gentiva(R) Health Services to Present March 18th at Lehman Brothers Eleventh Annual Global Healthcare Conference in Miami 2Health News:Gentiva(R) Health Services to Present March 18th at Lehman Brothers Eleventh Annual Global Healthcare Conference in Miami 3Health News:New Drug for Brain Cancer Too Dangerous for Pediatric Patients 2Health News:New Drug for Brain Cancer Too Dangerous for Pediatric Patients 3
(Date:10/22/2014)... , Oct. 22, 2014  Paper Pak Industries, ... developed APLS ® Body Guard Bio, a ... spread of bacteria and virus while protecting service ... Guard Bio features a rugged, external nylon shell, ... create a leak-proof inner chamber that contains contaminated ...
(Date:10/22/2014)... , October 22, 2014 A ... Gloves Market (Product type, Form, End user, Application and ... Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 ... gloves market. Based on key trends tracked, it is ... at $7.9 billion by 2020, registering a CAGR of ...
(Date:10/22/2014)... YARDLEY, Pa. , Oct. 22, 2014 /PRNewswire/ ... of their animal health medications, a Global Pharmaceutical ... and Antares serialization technology and turnkey solution to ... Photo - http://photos.prnewswire.com/prnh/20141021/153438 ... The product that was serialized and aggregated by ...
Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Xyntek and Antares Serialization Solution Protects Pets Too! 2
... Registration Trials, HAYWARD, Calif., Sept. 6 Kosan ... has successfully,reached a binding agreement with the U.S. Food ... clinical trial, a pivotal Phase 3 trial,of its Hsp90 ... Through the FDA,s Special Protocol Assessment (SPA),process, Kosan and ...
... Prevalence and Continuous,Abstinence by Dose, Schedule and Antibody Response; Nabi to ... ... Today, BOCA RATON, Fla., Sept. 5 Nabi,Biopharmaceuticals (Nasdaq: ... (Nicotine Conjugate Vaccine), the company,s,innovative and proprietary investigational vaccine being developed ...
Cached Medicine Technology:Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 2Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 3Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 4Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 5Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 6Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 7
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: